UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 85,926 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 49.4% in the third quarter, Holdings Channel reports. The institutional investor owned 88,021 shares of the company’s stock after selling 85,926 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in GoodRx were worth $611,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Rubric Capital Management LP boosted its stake in GoodRx by 25.2% during the 3rd quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock valued at $32,479,000 after purchasing an additional 943,226 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its position in shares of GoodRx by 260.7% during the third quarter. Dynamic Technology Lab Private Ltd now owns 44,419 shares of the company’s stock valued at $308,000 after buying an additional 32,104 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in GoodRx by 5.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock worth $3,332,000 after buying an additional 26,262 shares in the last quarter. Quest Partners LLC purchased a new stake in GoodRx in the 3rd quarter valued at $160,000. Finally, CWA Asset Management Group LLC bought a new position in GoodRx during the 3rd quarter valued at $370,000. 63.77% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on GDRX shares. Citigroup reduced their target price on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Morgan Stanley decreased their price objective on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday. Barclays cut their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Finally, Mizuho assumed coverage on GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price target for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, GoodRx has an average rating of “Moderate Buy” and an average target price of $8.37.

GoodRx Price Performance

NASDAQ GDRX opened at $4.44 on Friday. The company has a market cap of $1.69 billion, a PE ratio of -148.00, a price-to-earnings-growth ratio of 3.54 and a beta of 1.29. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm’s 50-day simple moving average is $5.33 and its two-hundred day simple moving average is $6.97. GoodRx Holdings, Inc. has a 52 week low of $4.09 and a 52 week high of $9.26.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.